• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    11/14/24 7:51:22 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email
    SC 13G/A 1 p24-3230sc13ga.htm CYBIN INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Cybin Inc.

    (Name of Issuer)
     

    Common Shares, no par value

    (Title of Class of Securities)
     

    23256X407

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 23256X40713G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    292,397 shares of common stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    292,397 shares of common stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    292,397 shares of common stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.4%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 23256X40713G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    292,397 shares of common stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    292,397 shares of common stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    292,397 shares of common stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.4%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 23256X40713G/APage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    292,397 shares of common stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    292,397 shares of common stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    292,397 shares of common stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.4%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 23256X40713G/APage 5 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
      Cybin Inc. (the “Issuer”).
    Item 1(b). Address of Issuer's Principal Executive Offices.
      100 King Street West, Suite 5600, Toronto, Ontario, Canada M5X 1C9.

     

    Item 2(a). Name of Person Filing.
     

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common shares, no par value (“Shares”), of the Issuer held by (and underlying warrants held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by (and underlying warrants held by) an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Shares, no par value.
       
    Item 2(e). CUSIP Number.
      23256X407

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on September 30, 2024.

     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

     

    CUSIP No. 23256X40713G/APage 6 of 7 Pages

     

     

      The aggregate percentage of the Shares reported to be beneficially owned by each Reporting Person is based on 20,284,304 Shares outstanding, which is the sum of: (i) 19,991,907 Shares outstanding, as reported in Exhibit 99.2 attached to the Issuer’s Current Report on Form 6-K filed with the Securities and Exchange Commission on September 20, 2024; and (ii) 292,397 warrant shares exercised as reported herein.
       
    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      See Item 2(a).
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
      Not applicable.

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 23256X40713G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
     

    Title: Authorized Person

     

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
       
      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      

     

     

    Get the next $CYBN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    SEC Filings

    See more
    • SEC Form 6-K filed by Cybin Inc.

      6-K - CYBIN INC. (0001833141) (Filer)

      6/3/25 5:18:12 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cybin Inc.

      6-K - CYBIN INC. (0001833141) (Filer)

      5/22/25 4:20:09 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Cybin Inc.

      SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)

      5/21/25 4:52:11 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Financials

    Live finance-specific insights

    See more
    • Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

      - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

      11/18/24 7:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

      - Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

      11/14/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

      - Breakthrough Therapy Designation ("BTD") provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration ("FDA") guidance on trial design, with the potential to significantly reduce drug development timelines - - First known BTD granted by the FDA for an adjunctive psychedelic based therapy for the treatment of Major Depressive Disorder ("MDD") - - Robust, sustained and statistically significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses (16mg) - - Impressive mean 22-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline at four months -

      3/13/24 6:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

      - Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ("DMT") and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 - - Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004

      6/3/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a Water Tower Research Fireside Chat taking place on Thursday, May 29, 2025, at 11:00 a.m. ET. The fireside chat will be hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research. Covered topics will include: The evolution of interventional psychiatry clinics and the importance of Cybin's partnership with Osmind. Progress of the CYB003 Phase 3 p

      5/22/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

      - U.S. Food and Drug Administration ("FDA") Commissioner identifies psychedelic drug development as a top agency priority in an effort to address unmet needs in mental health - - Calls for FDA to be open to innovative treatments that show promise, even when they challenge traditional understanding of medicine - - CYB003 granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder ("MDD") - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent com

      5/20/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Cybin with a new price target

      Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

      3/13/25 7:34:44 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cybin with a new price target

      HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      11/22/21 6:24:49 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin downgraded by Maxim Group

      Maxim Group downgraded Cybin from Buy to Hold

      11/19/21 8:09:52 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

      - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform

      4/23/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

      - Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology - - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 - - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company")

      10/1/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) (Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on August 27, 2024 (the "Meeting"). There were 87 shareholders represented in person or by proxy at the Meeting holding 453,195,063 common shares, representing 59.66% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are

      8/27/24 7:01:00 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cybin Inc.

      SC 13G - CYBIN INC. (0001833141) (Subject)

      12/3/24 5:23:26 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 7:51:22 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 6:55:13 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care